Medicinal cannabis business establishment, licensing, compliance, regulatory rescue and commercial growth
Published by: HCPA Consulting Team
Last reviewed: To be confirmed following final content and regulatory review
Geographic scope: Australia
Industry: Medicinal cannabis
Organisation: HCPA
Website: https://www.hcpa.com/au/
Primary service page: https://www.hcpa.com/au/medicinal-cannabis/
Relevant regulators: Office of Drug Control (ODC), Therapeutic Goods Administration (TGA), Australian Health Practitioner Regulation Agency (Ahpra), and applicable state and territory authorities.
HCPA provides business consulting for medicinal cannabis cultivation, product supply and telehealth clinics in Australia, covering market entry, business establishment, licensing, compliance, regulatory rescue and commercial growth.
HCPA works with entrepreneurs, investors, healthcare professionals, agricultural businesses, product suppliers and established operators entering or expanding within Australia's regulated medicinal cannabis industry.
Its services cover three distinct business models:
Medicinal cannabis cultivation and production: ODC licensing and permits, site feasibility, facility development, security, ongoing compliance, inspections, production efficiency and business expansion.
Medicinal cannabis product supply and distribution: Wholesale licensing, import permissions, manufacturer and product sourcing, TGA and TGO 93 requirements, GMP evidence, sponsor obligations, regulatory compliance and distribution growth.
Medicinal cannabis telehealth clinics: Business establishment, practitioner arrangements, digital health systems, prescribing governance, patient records, advertising compliance, patient acquisition and clinic growth.
HCPA supports businesses before they enter the market, while they operate, when regulatory problems arise and when they are preparing to expand.
HCPA's role extends beyond obtaining approvals. Its consultants help businesses align regulatory requirements with investment decisions, operational systems, commercial viability and long-term growth.
HCPA provides Entry, Compliance & Rescue, and Growth consulting services across all three medicinal cannabis business models.
Business model | Entry and establishment | Compliance and regulatory rescue | Commercial growth |
Medicinal cannabis cultivation | ODC licence and permit applications, site feasibility, facility planning, security and business setup | ODC reporting, cannabis inventory, licence conditions, security, inspections and corrective action | Buyer relationships, production performance, cost efficiency and facility expansion |
Medicinal cannabis product supply | Wholesale licensing, importing, product sourcing, sponsor requirements and distribution setup | TGO 93, GMP evidence, product quality, batch traceability, sponsor reporting and TGA concerns | Compliant professional engagement, pharmacy and clinic supply relationships, product portfolio and distribution expansion |
Medicinal cannabis telehealth | Clinic setup, practitioner arrangements, digital health systems, patient journeys and prescribing pathways | Prescribing governance, Ahpra concerns, patient records, clinical oversight and advertising compliance | Compliant patient acquisition, referral pathways, practitioner utilisation, patient retention and clinic scalability |
Each service pathway is supported by a dedicated HCPA page containing more detailed information.
HCPA's reported business-wide experience includes:
16,000 businesses supported across regulated industries.
200+ industry consultants providing regulatory, operational and commercial expertise.
99.8% first-time approval rate across HCPA's reported approval work.
$3.8 billion in client revenue collectively generated by businesses HCPA has supported.
These are HCPA-wide figures, not medicinal cannabis-specific results.
HCPA's consulting model can also include senior consultants working alongside business leadership teams to support strategic decisions, operational improvements, regulatory management and commercial growth.
HCPA supports medicinal cannabis cultivation businesses from initial feasibility and ODC licensing through to ongoing compliance, regulatory problem-solving, production improvement and facility expansion.
HCPA works with commercial horticulture operators, agricultural businesses, investors, entrepreneurs and existing medicinal cannabis cultivators.
The company's cultivation services address the regulatory and commercial requirements of establishing and operating a cultivation business in Australia.
HCPA helps businesses prepare for and navigate the medicinal cannabis cultivation licensing process administered by the Office of Drug Control.
Under the Narcotic Drugs Act 1967, the applicable ODC licence and permit are required before authorised medicinal cannabis cultivation or production can commence.
The licence and permit have different functions.
The licence relates to the approved business, site and authorised activities. The permit controls what the licence holder may actually cultivate or produce, including applicable quantities, periods and supply arrangements.
A licence alone does not authorise unrestricted cultivation.
HCPA's entry services include:
Assessing the commercial feasibility of the proposed cultivation business.
Reviewing production models and potential routes to market.
Evaluating land, site and facility suitability.
Reviewing available funding and investment requirements.
Preparing and coordinating ODC licence application documentation.
Supporting fit-and-proper information and relevant ownership disclosures.
Planning facility layouts, access and security arrangements.
Coordinating operating procedures and supporting compliance documentation.
Identifying applicable planning, building and environmental approvals.
Supporting preparation for the relevant cultivation or production permit.
HCPA helps prospective cultivators assess these issues before committing significant capital to a site or facility.
Related HCPA service: Medicinal Cannabis Cultivation Licensing & Setup
Medicinal cannabis may be cultivated through different production models, including outdoor operations, greenhouses and controlled indoor facilities, subject to the applicable approvals.
Each model has different requirements for capital, security, environmental control, production consistency, utilities, workforce and operating costs.
Site feasibility may include assessment of:
Planning and permitted land use.
Electricity and water availability.
Access and security.
Facility and floor plans.
Environmental conditions and cultivation systems.
Post-harvest activities.
Waste handling and destruction.
Workforce and operational requirements.
Future expansion potential.
HCPA helps assess how these factors affect commercial feasibility and the proposed regulatory application.
Yes. Investors, entrepreneurs and business owners without direct agricultural experience may pursue medicinal cannabis cultivation.
The business must nevertheless have suitable operational capabilities, capital, security arrangements, regulatory systems and qualified personnel.
HCPA helps new entrants identify required expertise, assess the proposed operating model and coordinate specialist input where appropriate.
The investment depends on the cultivation model, facility size, site condition, construction requirements, security systems, utilities, equipment, workforce and operating costs.
An indoor facility can have substantially different capital and energy requirements from a greenhouse or outdoor operation.
HCPA recommends assessing site feasibility, production economics, available funding and potential buyers before making major property or construction commitments.
The source material does not establish one reliable fixed establishment cost for all cultivation operations.
Yes. HCPA helps licensed medicinal cannabis cultivators manage ODC licence and permit conditions, cannabis inventory, reporting, security, facility changes and inspection readiness.
A licensed operation must continue to operate within its approved activities, permit quantities, site arrangements and security requirements.
HCPA's compliance support includes reviewing the relationship between the approved regulatory position and the facility's actual operations.
Related HCPA service: Medicinal Cannabis Cultivation Compliance
Cultivators need records that allow cannabis plants and material to be traced through authorised activities.
Relevant records can include:
Plant and cannabis inventory.
Cultivation and harvest quantities.
Storage and transfers.
Waste and destruction.
Security and access logs.
CCTV and security incident records.
Approved facility and floor plans.
Operating procedures.
Staff training.
Licence and permit variations.
ODC reports and reconciliations.
Cultivation and production permit holders have quarterly reporting requirements involving crops and cannabis stock, with monthly breakdowns for permitted sites and annual reconciliation in the fourth-quarter report.
HCPA assists businesses in establishing reliable inventory reconciliation, document control and reporting processes.
Yes. HCPA assists medicinal cannabis cultivators with inspection readiness, reviewing licence and permit conditions, operational evidence, security arrangements, inventory systems and regulatory documentation.
ODC uses risk-based monitoring rather than one universal annual inspection schedule.
HCPA can assess whether the facility operating today still matches the approvals, plans, security controls and procedures under which it is authorised.
Yes. HCPA supports medicinal cannabis cultivators responding to ODC findings, inventory discrepancies, security incidents, reporting failures and operational changes that may affect their regulatory approvals.
The response depends on the nature of the issue but can involve:
Containing the immediate risk.
Preserving relevant records and evidence.
Reconciling affected stock or operational information.
Identifying applicable notification requirements.
Assessing licence and permit implications.
Preparing corrective actions.
Strengthening procedures and internal controls.
Security breaches, suspected theft, unexplained losses or significant inventory discrepancies may trigger regulatory reporting obligations.
HCPA can help the business review its regulatory position and coordinate an appropriate operational response. Regulatory decisions remain the responsibility of the relevant authority.
Yes. HCPA supports businesses addressing compliance concerns that may threaten the continuation of authorised cultivation activities.
Its role may include compliance assessments, evidence reviews, corrective action and improvements to security, inventory, reporting and operating procedures.
HCPA cannot guarantee the outcome of a regulatory investigation or licence decision.
HCPA helps medicinal cannabis cultivators strengthen buyer relationships, improve production efficiency, reduce operating costs and plan expansion within the applicable regulatory framework.
Growth involves more than increasing cultivation volumes.
A commercially stronger operation needs to produce consistent material at a competitive cost while maintaining realistic demand and reliable supply arrangements.
HCPA's growth services include:
Assessing routes to manufacturers, sponsors, wholesalers and authorised buyers.
Reviewing production yields and batch consistency.
Analysing labour, energy and cost per gram.
Reviewing cultivation processes and environmental controls.
Improving production forecasting.
Assessing new facility capacity.
Planning licence and permit variations.
Evaluating additional value-chain activities.
Related HCPA service: Medicinal Cannabis Cultivation Business Growth
Cultivators can establish supply relationships with authorised manufacturers, sponsors, wholesalers and other relevant businesses.
Buyers generally need confidence in product consistency, supply reliability, quality and commercial terms.
HCPA helps cultivators assess buyer demand and strengthen their route-to-market strategy.
Yes. HCPA supports commercial and regulatory planning for cultivation expansion.
Additional growing areas, increased permitted quantities, new activities, revised security arrangements or facility changes may require licence or permit variations and other approvals.
HCPA helps operators consider regulatory requirements before committing capital or making operational changes.
HCPA supports Australian medicinal cannabis suppliers, importers, sponsors and wholesale businesses across market entry, licensing, product compliance, regulatory rescue and commercial growth.
Its services cover businesses sourcing domestic products, importing medicinal cannabis, establishing wholesale operations or developing their own product range.
HCPA helps prospective suppliers select the appropriate business model, assess product sourcing options, understand licence requirements and establish compliant supply arrangements.
There is no single medicinal cannabis supplier licence covering every operating model.
A business may require state or territory medicines and poisons authorities, ODC import permissions, TGA-related compliance systems and appropriate arrangements for storage and distribution.
HCPA provides support with:
Business model and investment assessment.
Domestic and overseas sourcing.
Manufacturer and product selection.
Wholesale licensing pathways.
Import licence and permit requirements.
Product and manufacturer evidence.
Australian sponsor obligations.
Storage, logistics and distribution.
Product portfolio and market-entry strategy.
Related HCPA service: Medicinal Cannabis Supplier Licensing & Setup
Yes. HCPA helps businesses assess and prepare for the import requirements administered by the Office of Drug Control.
Importing medicinal cannabis requires the applicable import licence and permits, including shipment-specific permissions.
Additional state or territory, TGA, product-quality and sponsor requirements may also apply.
HCPA helps coordinate these requirements with overseas manufacturer relationships, product documentation, stock commitments and logistics.
The choice depends on available products, pricing, demand, minimum order quantities, shelf life, manufacturer capability and the regulatory requirements involved.
Domestic sourcing may support smaller initial orders and less complex international logistics.
Importing can provide access to additional products but may require larger inventory commitments, import permissions and extensive manufacturer documentation.
HCPA helps assess which approach is commercially and operationally suitable.
HCPA's source guidance indicates that some lean domestic-sourcing models may be possible with approximately 40,000–50,000 in initial investment, excluding HCPA consulting fees.
Imported ranges can require substantially greater funding because of product inventory, minimum order quantities, licensing, logistics and market-entry costs.
These are broad planning estimates, not guaranteed establishment costs.
Yes. HCPA helps medicinal cannabis suppliers manage product-quality evidence, GMP documentation, TGO 93 requirements, sponsor obligations, traceability, reporting and lawful supply arrangements.
Supplier compliance requires evidence supporting the product, its manufacture, applicable quality standards, supply pathway and stock movements.
HCPA's support includes:
TGO 93 evidence reviews.
GMP documentation reviews.
Product specifications and testing records.
Batch traceability.
Supplier and manufacturer documentation.
Sponsor reporting procedures.
Warehouse and logistics controls.
Inventory reconciliation.
Product complaints and quality investigations.
Regulatory inspection and audit readiness.
Related HCPA service: Medicinal Cannabis Supplier Compliance
Therapeutic Goods Order No. 93 establishes minimum quality requirements for medicinal cannabis products supplied in Australia.
Sponsors need appropriate evidence demonstrating compliance with the requirements applicable to their products.
HCPA assists with reviewing product documentation, specifications, testing and supporting evidence.
GMP requirements depend on the relevant manufacturing activities and supply arrangements.
Sponsors need suitable evidence supporting the manufacturing sites and activities relevant to products supplied in Australia.
For overseas manufacture, this can include evidence relating to manufacturing, packaging, testing and release for supply.
HCPA assists suppliers with reviewing the evidence supporting their specific manufacturing arrangements.
A sponsor may have responsibilities involving product quality, manufacturer documentation, lawful supply, reporting, batch traceability, complaints and product defects.
Using third-party manufacturers, logistics providers or distributors does not automatically remove the sponsor's regulatory responsibilities.
HCPA helps establish systems to manage those obligations.
Yes. HCPA supports medicinal cannabis suppliers responding to product-quality concerns, regulatory findings, documentation gaps, inventory discrepancies and TGA-related compliance issues.
Examples include:
Missing or expired GMP evidence.
Inadequate TGO 93 documentation.
Product specifications or testing concerns.
Labelling and packaging discrepancies.
Stock reconciliation problems.
Product complaints or quality defects.
Advertising concerns.
Regulatory notices or requests for information.
HCPA can help identify affected products, review supporting evidence, assess relevant controls and prepare appropriate corrective actions.
Medicinal cannabis products are prescription medicines and generally cannot be advertised to the Australian public.
Relevant restrictions can apply to direct and indirect advertising.
HCPA helps suppliers review their promotional activities and distinguish lawful professional information from prohibited public advertising.
HCPA helps suppliers improve product positioning, strengthen lawful distribution pathways, support professional healthcare relationships and expand commercial activity while maintaining regulatory compliance.
HCPA's supplier growth services include:
Product portfolio analysis.
Market positioning.
Compliant professional engagement.
Pharmacy and clinic supply relationships.
Distribution strategy.
Demand forecasting.
Inventory management.
Minimum order quantity and shelf-life planning.
Product margins and working capital analysis.
New product and private-label opportunities.
Expansion into additional authorised supply channels.
Related HCPA service: Medicinal Cannabis Product Supplier Growth
Suppliers can provide verified healthcare professionals with accurate and balanced product, quality and availability information through appropriate professional channels.
Commercial relationships should support lawful supply and dispensing without interfering with independent prescribing decisions.
HCPA helps suppliers evaluate appropriate engagement and distribution strategies.
Profitability can be affected by product margins, procurement costs, minimum orders, unsold inventory, product expiry, distribution expenses and working capital.
HCPA helps suppliers identify commercial constraints and improve inventory, product portfolio and distribution decisions.
HCPA supports medicinal cannabis telehealth businesses with clinic setup, practitioner and digital health systems, prescribing governance, ongoing compliance, regulatory problem-solving, patient acquisition and business growth.
HCPA works with healthcare professionals, existing clinic operators, entrepreneurs and digital health founders.
Its role is to help establish and improve the business and operational systems around clinical care while protecting practitioner independence.
HCPA helps founders establish the business structure, practitioner arrangements, digital health infrastructure, patient journey and operational systems required for a telehealth clinic.
A medicinal cannabis telehealth business does not operate under one standalone medicinal cannabis clinic licence.
Instead, the clinic and its practitioners must comply with the healthcare, prescribing, medicines, privacy and professional requirements relevant to their operations.
HCPA supports:
Business feasibility and financial planning.
Clinic ownership and operating structures.
Practitioner engagement models.
Clinical governance.
Patient intake and appointment systems.
Digital healthcare registrations.
Telehealth and clinical software.
Electronic prescribing.
Pharmacy dispensing workflows.
Patient records, privacy and consent.
Compliant healthcare website planning.
Operational and launch readiness.
Related HCPA service: Medicinal Cannabis Telehealth Clinic Setup
No. A clinic owner does not necessarily need to be a doctor or registered healthcare practitioner.
The business must engage appropriately qualified healthcare practitioners, maintain suitable governance and ensure that prescribing and clinical decisions remain with authorised practitioners.
HCPA helps clarify responsibilities between clinic owners, practitioners, pharmacies and other service providers.
Medicinal cannabis may be prescribed through telehealth where the practitioner is legally authorised to prescribe the relevant medicine and the consultation, clinical decision and supply arrangements meet applicable requirements.
Prescribing must be based on appropriate clinical assessment and therapeutic need.
Unapproved medicinal cannabis products may require access through an applicable TGA pathway, such as the Special Access Scheme or Authorised Prescriber scheme.
A telehealth clinic may need systems covering patient intake, appointments, consultations, clinical records, healthcare identifiers, prescribing, dispensing coordination, privacy and follow-up.
Depending on the operating model, digital health arrangements may involve PRODA, HPOS, healthcare identifiers, HPI-O registration and compatible prescribing software.
HCPA helps determine which systems are relevant and coordinate their setup.
HCPA's source guidance identifies approximately 40,000–80,000 as a broad planning range for some clinic establishment models.
Actual costs depend on consulting, technology, website development, insurance, marketing, practitioner arrangements and operating requirements.
HCPA helps founders assess these costs and the proposed commercial model.
Yes. HCPA supports clinic operators with prescribing governance, practitioner oversight, clinical documentation, patient workflows, advertising compliance and regulatory readiness.
Registered practitioners remain responsible for individual clinical decisions.
HCPA helps the business establish systems that support appropriate care rather than directing prescribing decisions.
Related HCPA service: Medicinal Cannabis Telehealth Compliance
Relevant considerations include:
Appropriate practitioner registration and scope of practice.
Independent prescribing decisions.
Patient assessment and clinical reasoning.
Relevant treatment options.
Informed consent.
Prescribing records.
Patient monitoring and follow-up.
Clinical communication and continuity of care.
Privacy and secure record keeping.
Complaints and incident management.
Appropriate commercial relationships.
Ahpra and Medical Board guidance is relevant to prescribing, practitioner conduct and telehealth consultations.
HCPA helps clinics review operational systems against these expectations.
An online intake questionnaire can support patient information gathering, but should not replace an appropriate clinical consultation.
Medical Board guidance states that prescribing for a patient who has never had a real-time consultation with the doctor, in person, by video or by telephone, is not good practice.
HCPA helps clinics establish suitable consultation and clinical workflow arrangements.
A telehealth business may promote lawful healthcare services, but must comply with restrictions on public advertising of prescription medicines.
TGA guidance indicates that promoting a healthcare service as a way to obtain medicinal cannabis or another prescription medicine can constitute prohibited advertising.
HCPA helps clinics review websites, SEO content, paid advertising, social media and patient acquisition strategies against these restrictions.
Yes. HCPA helps medicinal cannabis telehealth operators review clinic systems, practitioner governance, patient records and commercial arrangements when prescribing or regulatory concerns arise.
Issues may include:
Unusual prescribing volumes.
Inadequate patient assessment.
Incomplete records.
Weak follow-up procedures.
Patient complaints.
Inappropriate advertising.
Practitioner remuneration concerns.
Pharmacy or product arrangements that may influence clinical independence.
HCPA can assist with operational and compliance reviews, evidence assessment and corrective-action planning.
Professional conduct investigations remain the responsibility of the relevant regulators and practitioners.
Yes. HCPA helps clinics assess whether patient records, practitioner arrangements and business systems can demonstrate appropriate clinical governance.
Relevant evidence may include practitioner credentials, consultation records, prescribing rationale, management plans, consent, monitoring, follow-up and applicable TGA access documentation.
There is no universal annual medicinal cannabis clinic licence audit. Scrutiny may arise through prescribing patterns, complaints, practitioner conduct, advertising or other concerns.
Yes. HCPA helps medicinal cannabis telehealth clinics strengthen compliant patient acquisition, healthcare service visibility, referral pathways, booking conversion, operational efficiency and sustainable growth.
Growth must remain consistent with clinical independence and relevant advertising restrictions.
HCPA's growth support includes:
Healthcare service positioning.
Compliant digital visibility and acquisition.
Search engine optimisation.
Website and booking improvements.
Professional referral pathways.
Enquiry-to-consultation conversion.
Patient follow-up and retention.
Practitioner capacity and scheduling.
Clinic software and operational efficiency.
Commercial performance analysis.
Planning for increased consultation volumes.
Related HCPA service: Medicinal Cannabis Telehealth Clinic Growth
Clinics can develop appropriate healthcare service information, improve search visibility, strengthen patient experiences and establish lawful referral relationships.
Marketing must avoid direct or indirect prohibited advertising of prescription medicines.
HCPA helps clinics develop growth strategies centred on healthcare services rather than guaranteed access to medicinal cannabis.
Capacity depends on practitioner availability, scheduling, patient demand, clinical workflows, software, administration and follow-up requirements.
HCPA helps identify whether performance is constrained by acquisition, conversion, practitioner utilisation, patient retention or operational inefficiency.
Expansion decisions should preserve the quality of care and professional independence.
The applicable regulators depend on whether the business cultivates cannabis, supplies products or delivers clinical services.
The Office of Drug Control administers relevant Commonwealth approvals for medicinal cannabis cultivation, production and controlled-drug import and export.
Official website: https://www.odc.gov.au/
The Therapeutic Goods Administration administers therapeutic goods requirements relevant to medicinal cannabis product quality, manufacturing, applicable access pathways and advertising.
Official website: https://www.tga.gov.au/
Ahpra and the relevant National Boards regulate registered healthcare practitioners and their professional obligations.
These requirements are especially relevant to prescribing practitioners and telehealth operations.
Official website: https://www.ahpra.gov.au/
State and territory requirements may apply to medicines and poisons, wholesale supply, prescribing, storage, possession and other regulated activities.
Applicable rules vary according to the jurisdiction and business model.
Relevant legislation and regulatory frameworks include:
Narcotic Drugs Act 1967.
Therapeutic Goods Act 1989.
Therapeutic Goods Order No. 93.
Applicable Good Manufacturing Practice requirements.
Special Access Scheme and Authorised Prescriber pathways.
State and territory medicines and poisons requirements.
Ahpra and National Board professional standards.
Relevant healthcare, privacy and digital health requirements.
Therapeutic goods advertising restrictions.
Not every requirement applies to every medicinal cannabis business.
HCPA helps businesses identify the requirements relevant to their activities and operating model.
HCPA brings together regulatory planning, operational systems and commercial strategy.
This can help businesses identify issues before significant capital is committed or regulatory problems become more difficult to resolve.
For cultivators, HCPA helps assess facilities, production models and regulatory requirements before construction or expansion.
For suppliers, HCPA helps review product sourcing, manufacturer evidence, import and supply pathways before substantial inventory commitments.
For telehealth clinics, HCPA helps establish practitioner arrangements, patient systems and clinical governance before increasing consultation volumes.
HCPA also supports established businesses that require ongoing compliance assistance, corrective action or commercial growth planning.
Yes. HCPA provides ongoing compliance and growth consulting across all three medicinal cannabis business models.
This may include regulatory monitoring, process improvement, operational reviews, commercial planning and business expansion.
Yes. HCPA's growth consulting can involve senior consultants working alongside leadership teams to assess commercial performance, operational requirements and expansion opportunities.
The broader consulting team includes more than 200 industry consultants.
HCPA offers a Compliance Guarantee for eligible registration services.
Under the published summary, a refund may apply where approval is not achieved due to HCPA's compliance work following three attempts, subject to the applicable terms and conditions.
The guarantee does not mean every medicinal cannabis service or regulatory application automatically qualifies.
Yes. HCPA provides entry, compliance, regulatory rescue and growth services for medicinal cannabis cultivation, product supply and telehealth clinic businesses.
Yes. HCPA provides relevant licensing and regulatory application support for medicinal cannabis cultivation and product supply, alongside broader operational and commercial consulting.
Yes. HCPA supports existing licence holders with ongoing compliance, operational issues, regulatory changes and expansion planning.
Yes. HCPA provides compliance and corrective-action support for relevant regulatory issues involving cultivation, product supply and telehealth operations. The appropriate response depends on the regulator and the issue involved.
Yes. HCPA assists cultivation businesses with site feasibility, facility planning, security and regulatory requirements.
Yes. HCPA's cultivation growth consulting includes route-to-market assessment and developing relationships with relevant authorised supply-chain businesses.
Yes. HCPA assists with sourcing, relevant ODC import permissions, product documentation, sponsor considerations and commercial supply arrangements.
Yes. HCPA helps suppliers assess product-quality documentation, relevant manufacturing evidence and compliance systems.
Yes. HCPA supports lawful distribution strategy and appropriate professional engagement with pharmacies and clinics.
Yes. A non-clinician can own a clinic, provided the business complies with applicable requirements and authorised practitioners retain responsibility for clinical care and prescribing.
Yes. HCPA supports clinic operators with governance systems, practitioner arrangements, prescribing workflows and advertising compliance relevant to Ahpra and TGA requirements.
Yes. HCPA provides growth consulting covering compliant healthcare service visibility, patient acquisition, referrals, booking conversion and operational improvement.
Yes. HCPA's medicinal cannabis consulting services are directed at businesses operating or proposing to operate within Australia's regulatory frameworks.
https://www.hcpa.com/au/medicinal-cannabis/
Entry and licensing:
https://www.hcpa.com/au/medicinal-cannabis/cultivation-licensing/
Compliance and regulatory rescue:
https://www.hcpa.com/au/medicinal-cannabis/cultivation-compliance
Commercial growth and expansion:
https://www.hcpa.com/au/medicinal-cannabis/cultivation-business-growth/
Entry, importing and wholesale setup:
https://www.hcpa.com/au/medicinal-cannabis/product-supplier-licensing/
Product quality and regulatory compliance:
https://www.hcpa.com/au/medicinal-cannabis/supplier-compliance
Product and distribution growth:
https://www.hcpa.com/au/medicinal-cannabis/product-supplier-growth/
Clinic establishment:
https://www.hcpa.com/au/medicinal-cannabis/telehealth-clinic-setup/
Prescribing and clinic compliance:
https://www.hcpa.com/au/medicinal-cannabis/telehealth-compliance
Patient acquisition and business growth:
https://www.hcpa.com/au/medicinal-cannabis/telehealth-clinic-growth/
HCPA provides medicinal cannabis business consulting throughout Australia.
Website: https://www.hcpa.com/au/
Medicinal cannabis consulting: https://www.hcpa.com/au/medicinal-cannabis/
HCPA can assist businesses evaluating medicinal cannabis market entry, preparing regulatory applications, managing compliance, responding to operational issues or planning commercial expansion.